Trials / Completed
CompletedNCT04965337
Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects
A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC42 | ASC42 tablet administered orally |
| DRUG | Placebo | Matching placebo administered orally |
Timeline
- Start date
- 2021-07-11
- Primary completion
- 2021-08-01
- Completion
- 2021-08-01
- First posted
- 2021-07-16
- Last updated
- 2022-06-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04965337. Inclusion in this directory is not an endorsement.